G-CSF (Granulocyte Colony Stimulating Factor) is a naturally occurring Cytokine that stimulates production and antibacterial function in neutrophils, monocytes and other cells. G-CSF, an 18.8-kDa protein with 175 amino acid residues, is soluble. The activated macrophages of monocytes, macrophages, cell fibroblasts, osteoblasts, bone marrow, and endothelial cells produce the pleiotropic Cytokine.
Anti-GM-CSF/ CSF2 antibody has been shown specifically to affect the proliferation, differentiation, and activation of hematopoietic cell proliferation, differentiation, and activation. G-CSF can also be expressed in various cells, including carcinoma cells and myeloblastic Leukemia cells.
G-CSF can be encoded by two distinct DNA sequences. This results in two different G-CSF forms, a full-size, high-activity and shorter, lower-activity isoform. G-CSF is extremely conserved across species. It has been demonstrated to exert its biological functions via interaction with its receptor on the surfaces of certain carcinoma cell lines, hematopoietic granulocytes, and neutrophil progenitors.
G-CSF can be used in clinical therapy for many purposes, including treatment of neonatal infarctions, therapy of acute coronary infarctions, granulocyte transfusions in patients with neutropenia, in severe cases and sepsis and therapy in chronic autoimmune neutropenia. It is also approved for the treatment of acute myeloid and Sweet's syndromes and AIDS.
G-CSF has also been shown to be a marker for various carcinomas, such as bladder cancer. Additionally, dysfunction of this protein has been linked with Kostmann syndrome. Human GSF antibody recognizes G-CSF, a haematopoietic growth factor of 19.6kDa. It is a member of the CSF family.